In summary, evidence from studies on the effect of pre-analytical handling on biomarkers of MCI suggest that use of the CSF Aβ1-42, t-tau and p-tau as potential biomarkers for MCI or AD-MCI CSF would improve the interpretation of CSF amyloid biomarker results, by reducing the impact of these factors on outcome. Here, MAPT is linked to Alzheimer disease.